Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Published:2019-07 Issue:7 Volume:14 Page:1255-1265
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cho Byoung Chul,Obermannova Radka,Bearz Alessandra,McKeage Mark,Kim Dong-Wang,Batra Ullas,Borra Gloria,Orlov Sergey,Kim Sang-We,Geater Sarayut L.,Postmus Pieter E.,Laurie Scott A.,Park Keunchil,Yang Cheng-Ta,Ardizzoni Andrea,Bettini Anna C.,de Castro Gilberto,Kiertsman Flavia,Chen Zhe,Lau Yvonne Y.,Viraswami-Appanna Kalyanee,Passos Vanessa Q.,Dziadziuszko Rafal

Funder

Novartis

Bristol-Myers Squibb

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference11 articles.

1. Identification of the transforming EML4-ALK fusion gene in non–small-cell lung cancer;Soda;Nature,2007

2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

3. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non–small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study;Soria;Lancet,2017